Integral DiagnosticsASX:IDX -0.50%75 Gross Margin % is 95.50% as of Dec. 2025, which is 0% above its 10-year median of 95.22. GuruFocus rates ASX:IDX with a GF Score™ of 75/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 96.41% on this metric.
The historical rank and industry rank for Integral Diagnostics's Gross Margin % or its related term are showing as below:
ASX:IDX'
s Gross Margin % Range Over the Past 10 Years
Min: 94.64 Med: 95.22 Max: 95.56
Current: 95.56
During the past 10 years, the highestGross Margin % of Integral Diagnostics was 95.56%. The lowest was 94.64%. And the median was 95.22%.
ASX:IDX's Gross Margin % is ranked better than 96.41% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs ASX:IDX: 95.56
Integral Diagnostics had a gross margin of 95.50% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Integral Diagnostics was 0.00% per year.
Integral Diagnostics (ASX:IDX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Integral Diagnostics had a gross margin of 95.50% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Integral Diagnostics Gross Margin % Related Terms
Integral Diagnostics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Integral Diagnostics (ASX:IDX) has a Gross Margin % of 95.50% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Integral Diagnostics and its competitors. This is near median its historical median of 95.22. Over the past decade, Integral Diagnostics' Gross Margin % has ranged from 94.64 to 95.56. According to the industry distribution chart, Integral Diagnostics ranks #7 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 3.6%.
Is Integral Diagnostics' Gross Margin % too high?
Integral Diagnostics' current Gross Margin % of 95.50% is near median its 10-year median of 95.22. Over the past 10 years, this metric has ranged from a low of 94.64 to a high of 95.56. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Integral Diagnostics' value of 95.50% is 87.4% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #7 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #7 out of 195 companies for Gross Margin %. This places Integral Diagnostics in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 50.97. Integral Diagnostics' value of 95.50% is 87.4% above this benchmark. Historically, Integral Diagnostics' own Gross Margin % has ranged from 94.64 to 95.56 over the past decade. While the company's 10-year median is 95.22 vs. the industry median of 50.97, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Gross Margin % of 95.50% is 87.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Gross Margin % is 95.50%, which is near median its own 10-year median of 95.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current Gross Margin % is 95.50%, which is near median its 10-year median of 95.22 and 87.4% above the Medical Diagnostics & Research industry median of 50.97. Integral Diagnostics' overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Gross Margin % is 95.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Gross Margin %: 95.50% (near median its 10-year median of 95.22)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 87.4% above the Medical Diagnostics & Research median (#7 of 195)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
75GF Score
Get the complete analysis for ASX:IDX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
